<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Using Tumor Organoids to Identify Cancer Biomarkers

Using Tumor Organoids to Identify Cancer BiomarkersReview why and how to use 3D in vitro tumor organoids to identify cancer biomarkers.

The Value of Biomarkers in Oncology Drug Development

Cancer is an extremely heterogeneous disease, with individual patients showing widely differing responses to the same treatment. It’s therefore not surprising that approximately 97% of oncology clinical trials fail, but that a higher success rate is achieved when studies use a biomarker strategy for patient selection.

The use of cancer biomarkers has taken large steps forward in recent years, including a major advancement when the FDA approved pembrolizumab (Keytruda®, Merck) and larotrectinib (Vitrakvi®, Bayer) to treat cancer patients based on the presence of specific tumor biomarkers, rather than the location of the tumor or site at which the cancer originated.

With more than 6,000 investigational agents currently in development, there is a significant need to identify predictive biomarkers to stratify patients to provide the best chance for therapeutic success while enhancing patient safety. Developing robust and sensitive biomarkers early in the drug development process helps establish a biomarker-guided approach to identify the most promising candidate therapies at an early stage and tailor novel therapeutics for specific patient populations and cancer indications.

Why Use Tumor Organoids to Identify Cancer Biomarkers?

There remains a need for improved tools to discover new biomarkers, which are essential for improvements in cancer care. For biomarker identification, tumor models must faithfully recapitulate the original tumor, predict patients’ in vivo clinical response, and be amenable to high-throughput drug screening (HTS).

Tumor organoids offer a next-generation approach for biomarker identification. In particular, Hubrecht Organoid Technology (HUB) has developed optimized protocols to produce tumor organoids from a variety of primary human cancers. Tumor organoids established using HUB protocols recapitulate the genomic, morphological, and pathophysiological characteristics of their parental tumor, and these properties are maintained indefinitely in vitro. This provides highly clinically relevant 3D in vitro tumor models for biomarker identification.

Biobanks of patient-relevant tumor organoids have also been established to capture the spectrum of heterogeneity that exists in patient populations. Since these in vitro models are amenable to high throughput drug screening, they offer the possibility for studying biomarkers of response.

How to Identify Cancer Biomarkers Using Tumor Organoids

Since tumor organoids are highly patient-relevant in vitro models, they provide unique opportunities that are not typically available in standard 2D or 3D culture screens. However, an organoid-based platform for drug development needs to meet a series of requirements to offer significant benefits and take full advantage of these advanced preclinical models.

A Large Biobank of Models

To truly reflect the diversity of the patient population, a tumor organoid model collection should be extensive. The collection should include multiple models per tissue type and from several cancer indications to cover a variety of mutational and pharmacological profiles. This provides the opportunity to assess response across numerous models simultaneously and identify predictive biomarkers.

A Well-Annotated Collection

The power of tumor organoids is not just in the numbers. To be informative, organoid models should be sufficiently annotated with genomic profiling data. Gene signature and biomarker discovery for new agents or repurposed drugs can then be based on the baseline genomic data available.

Robust In Vitro Assays

An efficiently designed organoid-based screening platform needs to offer robust assays with well-established read outs. This includes cytotoxicity assays to detect organoid cell killing or validated assays to assess immuno-oncology agents. This provides confidence in the data generated, and allows responder and non-responder models for the drug target to be identified.

Capacity to Perform High-Throughput Screens (HTS)

This allows the quick screening of large numbers of models or drugs (and their combinations) and provides plenty of repeats (“n”) to enable powerful statistical analysis.

Bioinformatics/In Silico Support

Bioinformatics capabilities are needed to process the information acquired via HTS.

Follow Up In Vivo Models

The availability of follow on in vivo models is needed to either test a hypothesis or move to more complex systems. In an ideal scenario the in vivo models are derived from the same patient as the organoid models, although this is a very rare instance. Alternatively, matched organoids and PDX models offer a unique opportunity to validate in vitro data in an in vivo system predictive of patient response. These matched systems allow biomarkers to be further validated, as some aspects of tumor response cannot be recapitulated in vitro

Conclusion

Using tumor organoids to identify cancer biomarkers in preclinical population studies offers an innovative new biomarker discovery approach. It’s possible due to biobanks of well-characterized and annotated tumor organoids recapitulating the heterogeneity observed in patient populations.

In addition, they are amenable to retrospective analyses that can validate biomarker expression and patient drug response, and because tumor organoids are an in vitro platform, they can be used for high-throughput drug screening to test drug response based on stratification of the identified biomarker(s).


Related Posts